SOD1 and amyotrophic lateral sclerosis: Furthermore, a double-blind, placebo-controlled safety and tolerability trial of arimoclomol in patients with rapidly progressive SOD1 ALS (which also recorded preliminary efficacy data) showed that arimoclomol is safe and well-tolerated, and although not powered for therapeutic effect, the results of the efficacy outcome measures suggested a possible therapeutic benefit of arimoclomol [34].